SYNJ1

synaptojanin 1, the group of Phosphoinositide phosphatases

Basic information

Region (hg38): 21:32628759-32728040

Links

ENSG00000159082NCBI:8867OMIM:604297HGNC:11503Uniprot:O43426AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • early-onset Parkinson disease 20 (Strong), mode of inheritance: AR
  • young-onset Parkinson disease (Supportive), mode of inheritance: AR
  • atypical juvenile parkinsonism (Supportive), mode of inheritance: AR
  • undetermined early-onset epileptic encephalopathy (Supportive), mode of inheritance: AD
  • developmental and epileptic encephalopathy, 53 (Moderate), mode of inheritance: AR
  • early-onset Parkinson disease 20 (Strong), mode of inheritance: AR
  • developmental and epileptic encephalopathy, 53 (Strong), mode of inheritance: AR
  • early-onset Parkinson disease 20 (Moderate), mode of inheritance: AR
  • genetic developmental and epileptic encephalopathy (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Developmental and epileptic encephalopathy 53; Parkinson disease 20, early-onsetARNeurologicFor Parkinson disease 20, response to levodopa has been describedNeurologic23804563; 23804577; 27435091

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SYNJ1 gene.

  • Early-onset_Parkinson_disease_20 (1058 variants)
  • Developmental_and_epileptic_encephalopathy,_53 (1057 variants)
  • not_provided (146 variants)
  • Inborn_genetic_diseases (111 variants)
  • SYNJ1-related_disorder (18 variants)
  • not_specified (6 variants)
  • Developmental_and_epileptic_encephalopathy,_1 (4 variants)
  • Young-onset_Parkinson_disease (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SYNJ1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000203446.3. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
269
clinvar
5
clinvar
277
missense
2
clinvar
1
clinvar
495
clinvar
26
clinvar
2
clinvar
526
nonsense
12
clinvar
3
clinvar
2
clinvar
17
start loss
0
frameshift
17
clinvar
2
clinvar
1
clinvar
20
splice donor/acceptor (+/-2bp)
1
clinvar
8
clinvar
2
clinvar
1
clinvar
12
Total 32 14 503 296 7

Highest pathogenic variant AF is 0.0000116291

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SYNJ1protein_codingprotein_codingENST00000433931 3299291
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.4270.5731256870611257480.000243
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.256678520.7830.000044610473
Missense in Polyphen214356.610.600094369
Synonymous0.4092953040.9700.00001633181
Loss of Function6.611984.50.2250.00000480994

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0006770.000674
Ashkenazi Jewish0.00009920.0000992
East Asian0.0002230.000217
Finnish0.00009530.0000924
European (Non-Finnish)0.0001940.000193
Middle Eastern0.0002230.000217
South Asian0.0005880.000588
Other0.0001640.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Phosphatase that acts on various phosphoinositides, including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate (PubMed:27435091). Has a role in clathrin-mediated endocytosis (By similarity). Hydrolyzes PIP2 bound to actin regulatory proteins resulting in the rearrangement of actin filaments downstream of tyrosine kinase and ASH/GRB2 (By similarity). {ECO:0000250|UniProtKB:O18964, ECO:0000250|UniProtKB:Q62910, ECO:0000269|PubMed:27435091}.;
Disease
DISEASE: Parkinson disease 20, early-onset (PARK20) [MIM:615530]: An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia. {ECO:0000269|PubMed:23804563, ECO:0000269|PubMed:23804577, ECO:0000269|PubMed:27496670}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Epileptic encephalopathy, early infantile, 53 (EIEE53) [MIM:617389]: A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. EIEE53 inheritance is autosomal recessive. {ECO:0000269|PubMed:27435091}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Inositol phosphate metabolism - Homo sapiens (human);Phosphatidylinositol signaling system - Homo sapiens (human);Phosphatidylinositol Phosphate Metabolism;Joubert syndrome;EGF-EGFR Signaling Pathway;D-<i>myo</i>-inositol (1,3,4)-trisphosphate biosynthesis;superpathway of D-<i>myo</i>-inositol (1,4,5)-trisphosphate metabolism;Vesicle-mediated transport;endocytotic role of ndk phosphins and dynamin;Membrane Trafficking;Metabolism of lipids;1D-<i>myo</i>-inositol hexakisphosphate biosynthesis II (mammalian);Inositol phosphate metabolism;3-phosphoinositide degradation;D-<i>myo</i>-inositol (1,4,5)-trisphosphate degradation;Metabolism;superpathway of inositol phosphate compounds;Clathrin-mediated endocytosis;Synthesis of IP3 and IP4 in the cytosol;Inositol phosphate metabolism;Synthesis of PIPs at the plasma membrane;PI Metabolism;Phospholipid metabolism;Synthesis of IP2, IP, and Ins in the cytosol;Internalization of ErbB1;EPHB forward signaling (Consensus)

Recessive Scores

pRec
0.121

Intolerance Scores

loftool
0.0251
rvis_EVS
0.5
rvis_percentile_EVS
79.67

Haploinsufficiency Scores

pHI
0.724
hipred
Y
hipred_score
0.685
ghis
0.590

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.988

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumHigh
CancerHighMediumHigh

Mouse Genome Informatics

Gene name
Synj1
Phenotype
vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype;

Zebrafish Information Network

Gene name
synj1
Affected structure
neuromast hair cell
Phenotype tag
abnormal
Phenotype quality
amount

Gene ontology

Biological process
phosphatidylinositol biosynthetic process;neurotransmitter transport;brain development;learning;synaptic vesicle priming;synaptic vesicle uncoating;phosphatidylinositol-3-phosphate biosynthetic process;inositol phosphate metabolic process;phosphatidylinositol metabolic process;inositol phosphate dephosphorylation;phosphatidylinositol dephosphorylation;synaptic vesicle endocytosis;synaptic vesicle transport;membrane organization;positive regulation of endosome organization
Cellular component
cytosol;microtubule;vesicle membrane;membrane coat;clathrin coat of coated pit;terminal bouton;perinuclear region of cytoplasm;synaptic membrane;presynapse;postsynapse
Molecular function
RNA binding;phosphatidylinositol-3-phosphatase activity;phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity;SH3 domain binding;phosphatidylinositol phosphate 5-phosphatase activity;phosphatidylinositol phosphate 4-phosphatase activity;phosphatidylinositol-4-phosphate phosphatase activity;phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity;phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity;inositol-1,4,5-trisphosphate 5-phosphatase activity;inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity